AN9025 oral capsule
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors (Phase 1)
Conditions
Solid Tumors (Phase 1), RAS Mutation
Trial Timeline
Jan 28, 2026 → Jun 1, 2028
NCT ID
NCT07252479About AN9025 oral capsule
AN9025 oral capsule is a phase 1 stage product being developed by Adlai Nortye for Solid Tumors (Phase 1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07252479. Target conditions include Solid Tumors (Phase 1), RAS Mutation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07252479 | Phase 1 | Recruiting |
Competing Products
20 competing products in Solid Tumors (Phase 1)